Effects of Tongmai Yangxin pills on ventricular remodeling in myocardial ischemia-reperfusion rats

Abstract

Objective: This study aimed to determine whether Tongmai Yangxin pills (TM) can attenuate ventricular remodeling (VR) and to explore the underlying mechanisms.
Methods: After the myocardial ischemia-reperfusion (I/R) injury model has been established, the rats were divided into seven groups: control, Sham, I/R, TM (1.0 g/kg), TM (2.0 g/kg), TM (4.0 g/kg), and Tongxinluo capsules, respectively. Experimental parameters were assessed on days 3 and 28 after drug administration. Cardiac structure and function were assessed by echocardiography. Myocardial ischemia was quantified using triphenyl tetrazolium chloride staining, and the cardiac pathology was evaluated using hematoxylin-eosin staining. Myocardial enzyme and oxidant activities were detected using an automatic biochemical analyzer and kit, respectively. Masson's trichrome staining was used to analyze the degree of collagen deposition. The expression levels of inflammation and fibrosis-related proteins were detected using enzyme-linked immunosorbent assays.
Results: After 3 days of administration, TM improved cardiac function and morphology. It effectively reduced the area of myocardial infarction in I/R rats, inhibited the abnormal activity of myocardial enzymes, and significantly reduced superoxide dismutase activity, as well as C-reactive protein, tumor necrosis factor-α, and interleukin-1β expression at the protein level. TM administration inhibited oxidative stress, inflammation, and myocardial pathological damage. After 28 d of administration, TM improved heart function; inhibited ventricular dilation and the thinning of the ventricular wall; significantly reduced the protein expression of connective tissue growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9; and decreased the degree of myocardial fibrosis.
Conclusions: TM can effectively reduce the infarct size, improve the cardiac structure and function, reduce myocardial collagen deposition, and attenuate VR. The underlying mechanisms involve the inhibition of inflammatory responses in the early stages and a reduction of myocardial fibrosis in the late stages.

Keywords

Myocardial ischemia-reperfusion / Tongmai Yangxin pills / Ventricular remodeling

References

[[1]] Yellon DM, Hausenloy DJ.Myocardial reperfusion injury. N Engl J Med 2007;357(11):1121-1135.

[[2]] Hausenloy DJ, Yellon DM.Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 2013;123(1):92-100.

[[3]] Florea VG, Mareyev VY, Samko AN, et al.Left ventricular remodelling: common process in patients with different primary myocardial disorders. Int J Cardiol 1999;68(3):281-287.

[[4]] Zornoff LA, Paiva SA, Duarte DR, et al.Ventricular remodeling after myocardial infarction: concepts and clinical implications. Arq Bras Cardiol 2009;92(2):150-164.

[[5]] Nian M, Lee P, Khaper N, et al.Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004;94(12):1543-1553.

[[6]] Hou ZL, Rui X.Clinical observation on 60 cases of angina pectoris of coronary heart disease with deficiency of qi and yin and blood stasis treated by Tongmai Yangxin pill. World Latest Med Inform 2019;19(26):132-134.

[[7]] Xu H.Observation on effect of Tongmai Yangxin pill combined with metoprolol on angina pectoris in patients with coronary heart disease. Doctor 2018;3(5):50-51.

[[8]] Wang YQ, Liu JL, Xu PG, et al.Clinical observation on the treatment of atrial fibrillation with Tongmai Yangxin pill. Chin J Evid Based Cardiovasc Med 2020;12(8):988-995.

[[9]] Di J, Liu L, Huang SH, et al.Tongmai Yangxin Wan for atrial arrhythmias of coronary heart disease: a clinical study. Chin J Evid Based Cardiovasc Med 2019;11(7):856-858.

[[10]] Wang Y, Wang X, Wang J, et al.Tongmai Yangxin intervening in myocardial remodeling after PCI for coronary heart disease: study protocol for a double-blind, randomized controlled trial. Trials 2020;21(1):287.

[[11]] Wu LH, Chen Q, Zhang B.Clinical observation of Tongmai Yangxin pills and compound Danshen tablets in treating 54 cases with chronic stable angina qi-deficiency and blood-stasis syndromes. Chin J Exp Tradit Med Formul 2015;21(15):172-175.

[[12]] Huang XT, Bai BQ, Li ZH, et al.Clinical study of Tongmai Yangxin pills combined with tirofiban in treatment of unstable angina pectoris. Drugs Clinic 2021;36(1):59-63.

[[13]] Tian YJ, Di J.Therapeutic effects of Tongmaiyangxin pill combined with beta blocker on coronary heart disease arrhythmia. Hebei Med J 2021;43(1):71-77.

[[14]] Cui Y, Li C, Zeng C, et al.Tongmai Yangxin pills anti-oxidative stress alleviates cisplatin-induced cardiotoxicity: network pharmacology analysis and experimental evidence. Biomed Pharmacother 2018;108:1081-1089.

[[15]] Cai X, Du J, Li L, et al. Clinical metabolomics analysis of therapeutic mechanism of Tongmai Yangxin pill on stable angina. J Chromatogr B Analyt Technol Biomed Life Sci 2018;1100-1101:106-112.

[[16]] Guo R, Liu N, Liu H, et al.High content screening identifies licoisoflavone A as a bioactive compound of Tongmaiyangxin pills to restrain cardiomyocyte hypertrophy via activating Sirt3. Phytomedicine 2020;68:153171.

[[17]] Wang Y, Zhang L, Xiao Y.The effect of Tongmai Yangxin pill on the inflammatory factors and oxidative stress induced by hypoxia-induced myocardial cells. Chin J Tradit Chin Med 2011;52(4):326-328.

[[18]] Chen R, Chen T, Wang T, et al.Tongmai Yangxin pill reduces myocardial no-reflow by regulating apoptosis and activating PI3K/Akt/eNOS pathway. J Ethnopharmacol 2020;261:113069.

[[19]] Chen R, Chen T, Wang T, et al.Tongmai Yangxin pill reduces myocardial No-reflow via endothelium-dependent NO-cGMP signaling by activation of the cAMP/PKA pathway. J Ethnopharmacol 2021;267:113462.

[[20]] Pfeffer MA, Braunwald E.Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81(4):1161-1172.

[[21]] McKay RG, Pfeffer MA, Pasternak RC, et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation 1986;74(4):693-702.

[[22]] Gao ZH, Lu SH, Zhao QT.Active ingredients and mechanism of traditional Chinese medicine for protection of myocardial ischemia. Chin J Tradit Chin Med Pharm 2015;30(1):170-173.

[[23]] Siwik DA, Colucci WS.Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev 2004;9(1):43-51.

[[24]] Iyer RP, de Castro Brás LE, Jin YF, et al. Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res 2014;114(5):860-871.

[[25]] Tron K, Manolov DE, Röcker C, et al.C-reactive protein specifically binds to Fcgamma receptor type I on a macrophage-like cell line. Eur J Immunol 2008;38(5):1414-1422.

[[26]] Toda N, Mukoyama M, Yanagita M, et al.CTGF in kidney fibrosis and glomerulonephritis. Inflamm Regen 2018;38(1):14.

[[27]] Song B, Zhang ZZ, Zhong JC, et al.Loss of angiotensin-converting enzyme 2 exacerbates myocardial injury via activation of the CTGF-fractalkine signaling pathway. Circ J 2013;77(12):2997-3006.

[[28]] Au CG, Butler TL, Sherwood MC, et al.Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy. Int J Exp Pathol 2011;92(1):57-65.

[[29]] Koitabashi N, Arai M, Kogure S, et al.Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension 2007;49(5):1120-1127.

[[30]] Tarin C, Lavin B, Gomez M, et al.The extracellular matrix metalloproteinase inducer EMMPRIN is a target of nitric oxide in myocardial ischemia/reperfusion. Free Radic Biol Med 2011;51(2):387-395.

[[31]] Ferreira JM, Ferreira SM, Ferreira MJ, et al.Circulating biomarkers of collagen metabolism and prognosis of heart failure with reduced or mid-range ejection fraction. Curr Pharm Des 2017;23(22):3217-3223.

RIGHTS & PERMISSIONS

2023 Acupuncture and Herbal Medicine